Abstract library

20 results for "Paran".
#2811 Improving Diagnosis Times as Part of the Transformation of the South Wales NET Service
Introduction: Transformation of the South Wales NET service in late 2017 introduced new specialised staff, gastroenterology-led clinics and improved MDTs with a particular emphasis on educating referring specialties. This has led to improved overall patient experience, satisfaction and quality of life. NETs are recognised world-wide for their lengthy diagnosis times.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Kapish Amin
#2950 Hemicolectomy for Neuroendocrine Neoplasms of the Appendix - Is It Really Necessary?
Introduction: Appendical neuroendocrine neoplasms (ANENs) are rare. Limited data is available regarding prognosis and optimal treatment strategy in those tumors
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Orit Twito
Authors: Twito O, Klein N, Paran H, Avital S, ...
#2953 Temporal Trends in Incidence, Presentation and Work-Up of Neuroendocrine Neoplasms of the Appendix
Introduction: Although temporal trends in incidence and prognosis of neuroendocrine neoplasms have been described in the literature, data regarding trends in Appendiceal Neuroendocrine Neoplasms (ANENs) is limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Orit Twito
Authors: Twito O, Klein N, Paran H, Avital S, ...
#18 Long-acting release octreotide induce complete response in type 1 gastric carcinoid tumors
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually < 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. The neoplastic ECL cells become progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there is a substantial decrease in argynophil and IR NE cells that can be visualized by conventional methods. ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumor progression. Such ECLomas deserve early, active, radical surgical treatment.
Traditionally, gastric carcinoid type 1 (GCA1s) are endoscopically or surgically removed, depending on the number, appearance and size of the tumors. Antrectomy, with surgical excision of the majority of the G cells, is thought to facilitate regression of these tumors by removing the source of excessive gastrin secretion; however, the long-term benefits of antrectomy still remain uncertain. Although proton pump inhibitors are effective in reducing hypergastrinemia-induced gastric acid hypersecretion in GCA2, they do not affect ECL-cell hyperplasia, and therefore their role in GCA1 is limited. Moreover, in selected cases, significant reduction of hypergastrinemia does not prevent development of ECL carcinoid, suggesting that, in addition to hypergastrinemia, other pathogenic or genetic factors may be involved. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. Treatment with SSAs in GCA1 leads to a substantial tumor load reduction, with a concomitant decrease of serum gastrin levels. Published data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. Morphometric studies demonstrated that, while antrectomy specifically decreased the volume of ECL cells versus the total volume of endocrine cells, octreotide reduces the overall endocrine cell volume. Although the number of treated patients is small, it has been suggested that SSA may exert important anti-proliferative effects either directly, by inhibiting ECL-cells proliferation, or indirectly through suppression of gastrin hypersecretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Ricardo Caponero
#449 Effective Treatment of a Metastatic Thymic Neuroendocrine Tumor with Capecitabine and Temozolomide: A Case Report
Introduction: Thymic neuroendocrine tumors are rare, with an estimated annual incidence of 0.2 per million. They are generally considered chemoresistant and there have been no reported cases of an objective response to therapy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Vita SarangaPerry
#485 Laparoscopic Surgery of Pancreatic Neuroendocrine Tumors: Results From a Tertiary Care Institution
Introduction: There are only a few series describing feasibility and short-term-outcome of laparoscopic surgery of pancreatic neuroendocrine tumors (pNET).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Sven-Petter Haugvik
#559 The Bone Scintigram in Patients with Neuroendocrine Tumors - A Series of 12 Cases
Introduction: The bone metastasis finding is based on imaging or aggressive features as high Ki-67 or rapidly progressive disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mara Carsote
Keywords: neuroendocrine, bone
#710 Characterization of Elderly Patients (≥70 Years) with Neuroendocrine Tumors (NETs)
Introduction: Incidence of NETs increases with age; however, age-specific epidemiologic analyses are lacking.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: María Isabel Sevilla García
Keywords: elderly, NETs
#798 Neuroendocrine Functions and Labyrinthectomy
Introduction: We tested the action of proline-rich peptide (PRP-1) and cobra venom Naja Naja Oxiana (NOX) on Deiters' nucleus neurons at 3rd, 15th and 35th days after unilateral labyrinthectomy (UL). Early and late tetanic, post-tetanic potentiation and depression of Deiters' neurons to bilateral high frequency stimulation of hypothalamic supraoptic and paraventricualar nuclei was studied. The analysis of spike activity was carried out by mean of on-line selection and special program.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Lilit Darbinyan
Authors: Darbinyan L, ...
#799 Action of the Hypothalamic Proline-Rich Peptide During Vestibular Compensation Following Unilateral Labyrinthectomy
Introduction: There are uncovered mechanisms of the vestibular compensation (VC), following unilateral labyrinthectomy (UL). We consider the hypothalamic proline-rich peptide (PRP-1) action on Deiters’ lateral vestibular nucleus (LVN) neurons upon dynamics of recovery after UL was carried out.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Research Fellow Lilia Hambardzumyan
Authors: Hambardzumyan L, ...